Gilteritinib is primarily metabolized via cytochrome P450 (CYP). Therefore, concomitant administration of strong CYP3A4 inducers or inhibitors is not recommended. We evaluated the incidence of gilteritinib-related adverse events (AEs) in 47 patients who received gilteritinib with or without antifungal triazoles which are known inhibitors of CYP3A4. Reasons for coadministration were antifungal prophylaxis or treatment of suspected or confirmed fungal diseases. Gilteritinib-related AEs were similar in the gilteritinib-triazole group compared to the gilteritinib without triazole group (75 % vs. 55.5 %, P = 0.23). Additionally, severity of AEs, gilteritinib dose reductions (15 % vs. 14.8 %) or discontinuation due to AEs (10 % vs. 22.2 %), and 90-day mortality (35 % vs. 11.1 %) were similar in both groups. Thus, concomitant gilteritinib and triazole therapy is feasible and is not associated with clinically meaningful increase in gilteritinib-related AEs.

Gilteritinib 主要通过细胞色素 P450 (CYP) 代谢。因此，不推荐同时使用强 CYP3A4 诱导剂或抑制剂。我们评估了 47 名接受 gilteritinib 联合或未联合抗真菌三唑类药物（已知的 CYP3A4 抑制剂）的 gilteritinib 相关不良事件 (AE) 的发生率。共同给药的原因是抗真菌预防或治疗疑似或确诊的真菌疾病。与不含三唑的 gilteritinib 组相比，gilteritinib-三唑组的 Gilteritinib 相关 AE 相似（75 % 与 55.5 %，P = 0.23）。此外，两组的 AE 严重程度、gilteritinib 剂量减少（15 % 对 14.8 %）或因 AE 停药（10 % 对 22.2 %）和 90 天死亡率（35 % 对 11.1 %）相似。因此，